日本厚生劳动省专家委员会周四批准了两款源自iPS细胞的再生医学产品商业化，这是全球首例。这些治疗针对严重心力衰竭和帕金森病患者，属于条件批准，需要收集长达七年的数据。iPS细胞研究先驱山中伸弥对此里程碑表示欣喜。
日本厚生劳动省专家委员会周四建议部长批准两款使用诱导多能干细胞（iPS细胞）的再生医学产品的生产和销售，这些产品有望成为全球首例此类产品之一。
日本委员会批准两款iPS细胞衍生药物 全球首例
由 AI 报道
相关文章
AI 生成的图像
McGill researchers use reversible drug approach to boost natural killer cells against hard-to-treat cancers
由 AI 报道 AI 生成的图像 事实核查
Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.
A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.
由 AI 报道
Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.
May 27, 2026 10:43